|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here we report efficacy and safety data of an Asian subset of the phase III FLAURA trial (NCT02296125), which compares osimertinib with standard of care (SoC) EGFR tyrosine kinase inhibitors (TKIs) in patients with previously untreated advanced NSCLC with tumors harboring exon 19 deletion (Ex19del)/L858R EGFR TKI-sensitizing mutations.
|
30240852 |
2019 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Fifty-six distinct uncommon <i>EGFR</i> mutations other than L858R, exon19del, exon20ins, or T790M were identified in 18.9% of patients with <i>EGFR</i>-mutant NSCLC.
|
30902917 |
2019 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Finally, we evaluated the concordance between plasma and tumour tissues by simultaneously detecting EGFR L858R by ddPCR and LNA-dPNA PCR clamp in 132 tissues and matched plasma samples from patients with NSCLC.
|
30663747 |
2019 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Collectively, compound <b>13</b>, a novel hederagenin-NO donor hybrid with a different chemical structure from those of the current FDA-approved EGFR-targeted anti-NSCLC drugs, may be a promising lead compound for the treatment of NSCLC expressing gefitinib-resistant EGFR with a T790 M mutation or osimertinib-resistant EGFR-LTC with an L858R/T790M/C797S mutation.
|
31718182 |
2019 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The antiproliferative activity of a dual PI3K/mTOR inhibitor BEZ235 was examined by the WST-1 assay and the soft agar colony-formation assay in 2 normal cell lines and 12 NSCLC cell lines: 6 expressing wild-type EGFR and 6 expressing EGFR with activating mutations, including exon 19 deletions, and L858R and T790 M point mutations.
|
31262325 |
2019 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Exon 19 deletion and L858R mutation in exon 21 of the epidermal growth factor receptor (EGFR) are both common mutations that predict a good response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).
|
26967328 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A total of 116 patients with completely resected II-IIIA NSCLC and confirmed positive EGFR mutation (exon 19 deletion or exon 21 Leu858Arg) between January 2013 and March 2017 were included in our study.
|
30369426 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Compound 23a displayed strong antiproliferative activity against the H1975 non-small cell lung cancer (NSCLC) cells bearing T790M/L858R.
|
29486953 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) with activating EGFR mutations, especially exon 19 deletions and the L858R point mutation, is particularly responsive to gefitinib and erlotinib.
|
29514601 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Thirty-six tissue samples from non-small-cell lung cancer (NSCLC) patients were detected by our method and 14/36 tissues gave EGFR L858R mutation-positive results, whereas ARMS-PCR just identified 12 of L858R mutant samples.
|
30128808 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Isolated metastasis of an EGFR-L858R-mutated NSCLC of the meninges: the potential impact of CXCL12/CXCR4 axis in EGFR<sub>mut</sub> NSCLC in diagnosis, follow-up and treatment.
|
29721166 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Multiple randomized clinical trials have demonstrated that epidermal growth factor receptor (EGFR) exon 19 deletion (19Del) and exon 21 L858R mutation (L858R) are highly correlated with sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in non-small-cell lung cancer (NSCLC).
|
29581983 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
<b>Methods</b> We retrospectively analyzed the clinical outcomes of 75 consecutive advanced NSCLC patients with EGFR-TKI sensitive mutations (exon 19 deletion or exon 21 L858R) received first-line gefitinib or erlotinib therapy according to weight loss status at presentation in our single center.
|
29483958 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
|
30030903 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We retrospectively evaluated the clinical effects and safety profiles of second-line cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with NSCLC harboring sensitive EGFR mutations (exon 19 deletion/exon 21 L858R mutation).
|
29737372 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
As a proof of concept study, we used the lab-on-a-disc to isolate cfDNA from patients with non-small cell lung cancer and successfully detected epidermal growth factor receptor gene mutations (L858R, T790M) during targeted drug therapy.
|
29658031 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A 67-year-old male who was initially diagnosed of EGFR L858R-mediated NSCLC received multiple lines of chemotherapy and EGFR TKI therapies after surgery.
|
29571986 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-positive (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a standard EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily).
|
29151359 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
This study potentially offers an innovative therapeutic avenue for the NSCLC with L858R/T790M-mutated EGFR.
|
30237564 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The presence of a deletion mutation in exon 19 or L858R point mutation in the EGFR kinase domain has been shown to cause enhanced efficacy of inhibitor treatment in patients with NSCLC.
|
29369805 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
AS-PCR analysis of treatment-naïve tumor samples revealed somatic T790M mutation in 3/394 (1%) non-small cell lung carcinomas (NSCLC) carrying the tyrosine kinase inhibitor (TKI)-sensitizing EGFR mutation, but in none of 334 NSCLC lacking EGFR exon 19 deletions (ex19del) or L858R substitutions and in none of 235 non-lung tumors.
|
30145586 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Increasing the treatment share of afatinib in a health plan for the first-line treatment of NSCLC with EGFR del19 or L858R mutations was estimated to increase the proportion of treated patients remaining in progression-free disease, while having small budget impact to the health plan.
|
29799327 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
|
30471829 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We treated a 38-year-old patient with NSCLC who carried the EGFR L858R mutation.
|
30127621 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The primary endpoint was the odds ratio (OR) of T790M mutation in NSCLC co-existing with L858R mutation and 19 del upon resistance to first-generation EGFR-TKIs.A random effects model was used.
|
29850136 |
2018 |